K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling

Area of Science:

• Molecular Biology
• Oncology
• Cell Signaling

Background:

• K-Ras and H-Ras mutations drive specific cancers, suggesting unique oncogenic roles despite shared effectors.
• Non-canonical Wnt/Ca2+ signaling is implicated in tumorigenesis, but its specific regulation by Ras isoforms is unclear.

Purpose of the Study:

• To investigate the differential roles of oncogenic K-Ras and H-Ras in non-canonical Wnt/Ca2+ signaling.
• To elucidate the molecular mechanisms by which K-Ras influences this pathway.
• To identify potential therapeutic targets for K-Ras-driven cancers.

Main Methods:

• Investigated K-Ras and H-Ras effects on Wnt/Ca2+ signaling in cancer cells.
• Utilized calmodulin binding assays and CaMKii activity measurements.
• Assessed Fzd8 expression and its role in tumorigenesis.
• Employed genetic manipulation and prostratin treatment to disrupt K-Ras-calmodulin interaction.

Main Results:

• Oncogenic K-Ras, but not H-Ras, suppresses non-canonical Wnt/Ca2+ signaling.
• K-Ras achieves this suppression by binding calmodulin, reducing CaMKii activity and Fzd8 expression.
• Restoring Fzd8 inhibited K-Ras mutant pancreatic cancer malignancy.
• Depleting Fzd8 enhanced tumor initiation in H-Ras-transformed cells.
• Disrupting K-Ras-calmodulin binding, via genetic means or prostratin, repressed K-Ras mutant pancreatic cancer growth.

Conclusions:

• K-Ras uniquely suppresses non-canonical Wnt/Ca2+ signaling, contributing to its oncogenic potential.
• The K-Ras-calmodulin interaction is a critical mediator of tumorigenesis.
• Targeting the K-Ras-calmodulin interaction, for example with prostratin, presents a promising therapeutic strategy for "undruggable" K-Ras mutant cancers.